Skip to content

Sarepta Therapeutics, Inc. SRPT Net gains (losses) on investments

Net gains (losses) on investments at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$1.21M+56.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$4.75M+79.7%
Precigen logo
PrecigenPGEN
$0+100%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$18.28M-17.5%
Arrowhead Research logo
Arrowhead ResearchARWR

Segments

By segment

See full
All Other Segments$1.71M-98.1%

Other financials

Income statement

See full
Revenue$730.8M-1.9%
Operating income-$300.4M-961%
Net income$331.0M+174%
EPS (diluted)-$4.60-1,343%

Balance sheet

See full
Cash & equivalents$464.5M+92.8%
Total debt$198.5M-3.4%
Total equity$1.5B+31.7%
Total assets$3.2B-8.3%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$2.1M-95.2%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.76B-63.1%

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin4.6%+2.4pp
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-23.6%-28.5pp
Debt / equity0.1×0.0×
Current ratio4.6×+0.6×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnInvestments.

The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sarepta Therapeutics, Inc.'s net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sarepta Therapeutics, Inc.'s net gains (losses) on investments?
Sarepta Therapeutics, Inc. (SRPT) reported net gains (losses) on investments of -$1.71M in Q1 2026.
How has Sarepta Therapeutics, Inc.'s net gains (losses) on investments changed year-over-year?
Sarepta Therapeutics, Inc.'s net gains (losses) on investments increased by 98.1% year-over-year, from -$90.73M to -$1.71M.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.